Psychometric evaluation of the 12-Item Short-Form Health Survey (SF-12) in osteoarthritis and rheumatoid arthritis clinical trials

Clinical Therapeutics

Volumn 23, Issue 7, 2001, Pages 1080-1098

  Gandhi, Sanjay K ^a,d   Warren Salmon, J ^a   Zhao, Sean Z ^b   Lambert, Bruce L ^a   Gore, Prasanna R ^c   Conrad, Kendon ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b PFIZER INC   (United States)

^c Gore and Company   (United States)

^d ASTRAZENECA   (United Kingdom)

Author keywords

Arthritis; Health status assessment; Psychometric properties; Quality of life; SF 12; Validation

Indexed keywords

NONSTEROID ANTIINFLAMMATORY AGENT;

ARTICLE; DAILY LIFE ACTIVITY; DRUG EFFICACY; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; OSTEOARTHRITIS; PSYCHOMETRY; QUALITY OF LIFE; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME;

EID: 0034900260     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(01)80093-X     Document Type: Article

References (48)

1. From outcomes research to disease management: A guide for the perplexed
2. The importance of health-related quality-of-life data in determining the value of drug therapy
3. Methodologic assessments of quality of life measures in clinical trials
4. Formulary decision making for evolving therapies
5. Economic evaluation of drugs and its potential uses in policy making
6. Recent developments and future issues in the use of health status assessment measures in clinical settings
7. Quality of life, health status, and clinical research
8. The baby boomers go gray
9. Change and status in quality of life in patients with rheumatoid arthritis
10. Personal models of osteoarthritis and their relation to self-management activities and quality of life
11. Recommendations for a core set of outcome measures for future phase III clinical trials in knee, hip, and hand osteoarthritis. Consensus development at OMERACT III
12. Measurement of functional status, quality of life, and utility in rheumatoid arthritis
13. Which outcomes measures should be used in rheumatoid arthritis clinical trials? Clinical and quality-of-life measures' responsiveness to treatment in a randomized controlled trial
14. The MOS 36-Item Short-Form Health Survey (SF-36). I. Conceptual framework and item selection
15. Comparison of methods for scoring and statistical analysis of SF-36 health profile and summary measure: Summary of results from the Medical Outcomes Study
16. The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs
17. The MOS 36-Item Short-Form Health Survey (SF-36): III. Tests of data quality, scaling assumption, and reliability across diverse patient groups
18. Construction and validation of an alternative form general mental health scale for the Medical Outcomes Study Short-Form 36-Item Health Survey
19. A 12-item Short-Form Health Survey: Construction of scales and preliminary tests of reliability and validity
20. Developing consensus on preliminary core efficacy endpoints for rheumatoid arthritis clinical trials
21. The scree-test for the number of factors
22. A seven-day variability study of 499 patients with peripheral rheumatoid arthritis
23. Comparison of auranofin, gold sodium thiomalate, and placebo in the treatment of rheumatoid arthritis. A controlled clinical trial
24. The assessment of disability: From first to future principles
25. Clinical studies with an articular index for the assessment of joint tenderness in patients with rheumatoid arthritis
26. Therapeutic criteria in rheumatic arthritis
27. Quality of life research and the health care industry
28. AIMS2: The content and properties of revised and expanded Arthritis Impact Measurement Scales Health Status Questionnaire
29. Quality-of-life measures in the evaluation of antihypertensive drug therapy: Reliability, validity and quality-of-life domains
30. Non-specific effects in longitudinal studies: Impact of quality of life measures
31. The placebo effect in cardiovascular disease
32. Placebo response in anxiety disorders
33. The uncontrollable placebo effect
34. Sexual quality-of-life of patients with arthritis compared to arthritis-free controls
35. Depression in rheumatoid arthritis
36. Barriers to use of health status measurement in clinical investigation, patient care, and policy research